Michele Cavo

Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma

E. Zamagni, P. Tacchetti, S. Barbato, 2024, Frontiers in Hematology.

Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology

A. Santoro, M. Gallieni, S. Pasquali, 2016, Journal of Nephrology.

High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients

E. Borsi, E. Zamagni, C. Terragna, 2023, Clinical and experimental medicine.

Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients

N. Manaresi, E. Borsi, E. Zamagni, 2024, Cancers.

Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients

E. Borsi, E. Zamagni, C. Terragna, 2024, Cells.

Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features

E. Borsi, E. Zamagni, N. Testoni, 2024, Nature communications.

Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma.

E. Zamagni, P. Tacchetti, S. Barbato, 2024, Expert opinion on biological therapy.